TOVX — Theriva Biologics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.84m
- -$7.62m
- 18
- 56
- 19
- 21
Annual cashflow statement for Theriva Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.1 | -14.3 | -19.7 | -18.3 | -25.7 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.528 | 0.416 | 2.57 | -1.84 | 7.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.78 | 0.875 | -0.623 | 2.7 | 1.18 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -12.2 | -12.9 | -19.1 | -19 | -16.9 |
| Capital Expenditures | -0.009 | -0.014 | -0.116 | -0.202 | -0.001 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -4.28 | 0 | — |
| Acquisition of Business | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.009 | -0.014 | -4.4 | -0.202 | -0.001 |
| Financing Cash Flow Items | — | — | -3 | -1.52 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.36 | 74 | -1.93 | 0.625 | 5.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -8.82 | 61.1 | -25.4 | -18.6 | -11.6 |